Skip to main content
Top

17-06-2024 | Amphotericin B | Original Article

Pre and Post Covid − 19 Experience of the ‘Amphotericin Sandwich’ Therapy in the Management of Mucormycosis

Authors: Samir Vinayak Joshi, Rajesh Radhakrishna Havaldar

Published in: Indian Journal of Otolaryngology and Head & Neck Surgery

Login to get access

Abstract

Mucormycosis is caused by saprophytic fungi belonging to the species mucorales. The disease commonly affects patients with immunocompromised states such as uncontrolled diabetes, blood disorders and organ transplantation recepients. The usual mode of management is by using antifungals such as amphotericin B and surgery in the form of debridement of the necrotic tissue. A study was conducted on patients of mucormycosis during the pre-Covid-19 and Covid-19 era to evaluate the effectiveness of the Sandwich Therapy of amphotericin B. The mortality rate was found to be 3.57% during the pre- Covid-19 period and 18.8% during the Covid-19 period. This is very low as opposed to 50% quoted by many other studies. The Sandwich Therapy as discussed above for extensive mucormycosis can be useful in curtailing the disease already established to its present location and preventing its further spread either naturally or by the act of debridement per se. It also provides a sustained anti fungal umbrella in the blood to deal with the disease at microscopic level in the blood stream thus reducing mortality.
Literature
3.
go back to reference Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K, Lass-Florl C, Bouza E, Klimko N, Gaustad P, Richardson M, Hamal P, Akova M, Meis JF, Rodriguez-Tudela JL, Roilides E, Mitrousia-Ziouva A, Petrikkos G, for the European Confederation of Medical Mycology Working Group on Zygomycosis (2011) Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 17:1859–1867. https://doi.org/10.1111/j.1469-0691.2010.03456.xCrossRefPubMed Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K, Lass-Florl C, Bouza E, Klimko N, Gaustad P, Richardson M, Hamal P, Akova M, Meis JF, Rodriguez-Tudela JL, Roilides E, Mitrousia-Ziouva A, Petrikkos G, for the European Confederation of Medical Mycology Working Group on Zygomycosis (2011) Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 17:1859–1867. https://​doi.​org/​10.​1111/​j.​1469-0691.​2010.​03456.​xCrossRefPubMed
4.
go back to reference Roden MM, Zaoutis TE, Buchanan WL et al (2005) Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 41:634–653CrossRefPubMed Roden MM, Zaoutis TE, Buchanan WL et al (2005) Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 41:634–653CrossRefPubMed
5.
go back to reference Spellberg B, Edwards J Jr, Ibrahim A (2005) Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 18:556–569CrossRefPubMedPubMedCentral Spellberg B, Edwards J Jr, Ibrahim A (2005) Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 18:556–569CrossRefPubMedPubMedCentral
10.
go back to reference Cornely OA, Arikan-Akdagli S, Dannaoui E, Groll AH, Lagrou K, Chakrabarti A, Lanternier F, Pagano L, Skiada A, Akova M, Arendrup MC, Boekhout T, Chowdhary A, Cuenca-Estrella M, Freiberger T, Guinea J, Guarro J, de Hoog S, Hope W, Johnson E, Kathuria S, Lackner M, Lass-Florl C, Lortholary O, Meis JF, Meletiadis J, Munoz P, Richardson M, Roilides E, Tortorano AM, Ullmann AJ, van Diepeningen A, Verweij P, Petrikkos G (2014) ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 20(Suppl 3):5–26. https://doi.org/10.1111/1469-0691.12371CrossRefPubMed Cornely OA, Arikan-Akdagli S, Dannaoui E, Groll AH, Lagrou K, Chakrabarti A, Lanternier F, Pagano L, Skiada A, Akova M, Arendrup MC, Boekhout T, Chowdhary A, Cuenca-Estrella M, Freiberger T, Guinea J, Guarro J, de Hoog S, Hope W, Johnson E, Kathuria S, Lackner M, Lass-Florl C, Lortholary O, Meis JF, Meletiadis J, Munoz P, Richardson M, Roilides E, Tortorano AM, Ullmann AJ, van Diepeningen A, Verweij P, Petrikkos G (2014) ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 20(Suppl 3):5–26. https://​doi.​org/​10.​1111/​1469-0691.​12371CrossRefPubMed
11.
go back to reference Ruping MJ, Heinz WJ, Kindo AJ, Rickerts V, Lass-Florl C, Beisel C, Herbrecht CR, Roth Y, Silling G, Ullmann AJ, Borchert K, Egerer G, Maertens J, Maschmeyer G, Simon A, Wattad M, Fischer G, Vehreschild J, Cornely OA (2010) Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother 65:296–302. https://doi.org/10.1093/jac/dkp430CrossRefPubMed Ruping MJ, Heinz WJ, Kindo AJ, Rickerts V, Lass-Florl C, Beisel C, Herbrecht CR, Roth Y, Silling G, Ullmann AJ, Borchert K, Egerer G, Maertens J, Maschmeyer G, Simon A, Wattad M, Fischer G, Vehreschild J, Cornely OA (2010) Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother 65:296–302. https://​doi.​org/​10.​1093/​jac/​dkp430CrossRefPubMed
12.
go back to reference Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll AH, Skiada A, Lass-Florl C, Calandra T, Viscoly C, Herbrecht R (2017) ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopooietic stem cell transplant patients. Haematologica 102:433–444CrossRefPubMedPubMedCentral Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll AH, Skiada A, Lass-Florl C, Calandra T, Viscoly C, Herbrecht R (2017) ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopooietic stem cell transplant patients. Haematologica 102:433–444CrossRefPubMedPubMedCentral
13.
go back to reference Cornely OA, Arikan-Akdagli S, Dannaoui E, Groll AH, Lagrou K, Chakrabarti A, Lanternier F, Pagano L, Skiada A, Akova M et al (2014) ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin. Microbiol. Infect. 2014, 20, 5–26 Cornely OA, Arikan-Akdagli S, Dannaoui E, Groll AH, Lagrou K, Chakrabarti A, Lanternier F, Pagano L, Skiada A, Akova M et al (2014) ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin. Microbiol. Infect. 2014, 20, 5–26
14.
go back to reference Chamilos G, Lewis RE, Kontoyiannis DP (2008) Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 47:503–509CrossRefPubMed Chamilos G, Lewis RE, Kontoyiannis DP (2008) Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 47:503–509CrossRefPubMed
15.
go back to reference Boelaert JR, de Locht M, Van Cutsem J et al (1993) Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest 91:1979–1986CrossRefPubMedPubMedCentral Boelaert JR, de Locht M, Van Cutsem J et al (1993) Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest 91:1979–1986CrossRefPubMedPubMedCentral
16.
go back to reference Van Cutsem J, Boelaert JR (1989) Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis). Kidney Int 36:1061–1068CrossRefPubMed Van Cutsem J, Boelaert JR (1989) Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis). Kidney Int 36:1061–1068CrossRefPubMed
17.
go back to reference Ibrahim AS, Gebermariam T, Fu Y et al (2007) The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 117:2649–2657CrossRefPubMedPubMedCentral Ibrahim AS, Gebermariam T, Fu Y et al (2007) The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 117:2649–2657CrossRefPubMedPubMedCentral
18.
go back to reference Caramalho R, Maurer E, Binder U, Araujo R, Dolatabadi S, Lass-Florl C, Lackner M (2015) Etest cannot be recommended for in vitro susceptibility testing of Mucorales. Antimicrob Agents Chemother 59:3663–3665CrossRefPubMedPubMedCentral Caramalho R, Maurer E, Binder U, Araujo R, Dolatabadi S, Lass-Florl C, Lackner M (2015) Etest cannot be recommended for in vitro susceptibility testing of Mucorales. Antimicrob Agents Chemother 59:3663–3665CrossRefPubMedPubMedCentral
Metadata
Title
Pre and Post Covid − 19 Experience of the ‘Amphotericin Sandwich’ Therapy in the Management of Mucormycosis
Authors
Samir Vinayak Joshi
Rajesh Radhakrishna Havaldar
Publication date
17-06-2024
Publisher
Springer India
Published in
Indian Journal of Otolaryngology and Head & Neck Surgery
Print ISSN: 2231-3796
Electronic ISSN: 0973-7707
DOI
https://doi.org/10.1007/s12070-024-04812-7